TL;DR
This study reveals that circulating microRNAs (miRNAs) in arterial blood, not just venous blood, show significant changes during hypertension. By analyzing both arterial and venous blood in rat models, the researchers identified specific arterial miRNAs that could serve as novel biomarkers for hypertension, suggesting a need to reconsider the reliance on venous samples for disease diagnostics.
What Problem Does This Paper Address?
The vast majority of research on circulating miRNA biomarkers for diseases, particularly cardiovascular diseases like hypertension, has focused on miRNAs found in peripheral venous blood. This is largely due to the ease of access and collection of venous blood samples. However, the authors point out that arterial blood, which directly perfuses tissues and organs, might offer a more direct reflection of disease-specific molecular changes. The problem is that the potential differences in miRNA profiles between arterial and venous blood, especially under disease conditions, have been largely overlooked. This oversight could lead to incomplete or even misleading biomarker identification if venous samples don't fully capture the disease's molecular signature. Hypertension, being a vascular disease, is a prime candidate to investigate these arterial-venous differences.
Methods
The study employed a multi-pronged approach:
- Next-Generation miRNA Sequencing: This was the primary tool to comprehensively profile circulating miRNAs in both arterial and venous blood samples from different rat groups.
- Bioinformatics Analysis:
- Differential Expression Analysis: Standard statistical methods (like DESeq2 and ANOVA) were used to identify miRNAs that were significantly different in expression between groups (e.g., hypertensive vs. control) and between sample types (arterial vs. venous).
- Disease Association Analysis (TAM 2.0): This tool was used to link the identified miRNAs to specific diseases based on existing literature.
- Target Gene Prediction (PITA, RNAhybrid, miRanda): These tools predicted potential genes that could be regulated by the identified miRNAs.
- Functional Enrichment Analysis (MSigDB): This helped understand the biological pathways and functions associated with the target genes.
- Transcription Factor (TF) Analysis (TransmiR v2.0): This identified upstream TFs that might regulate the expression of the deregulated miRNAs.
- Droplet Digital PCR (ddPCR): This highly sensitive technique was used to validate the expression levels of specific candidate miRNAs identified through sequencing.
Datasets
The study utilized blood samples from:
- Spontaneously Hypertensive Rats (SHR): A well-established animal model for essential hypertension.
- Wistar-Kyoto (WKY) Rats: The control group for SHR.
- Young Non-Hypertensive SHR Background Rats (JSHR): Used as a second control group to further validate findings, particularly for arterial miRNAs.
Both arterial (from the abdominal aorta) and venous (from the postcava) blood samples were collected from these animals at different ages (16 weeks for SHR/WKY, 5 weeks for JSHR).
Key Insights and Ideas
- Arterial vs. Venous miRNA Differences in Disease: While minimal differences were observed between arterial and venous miRNAs in healthy WKY rats, these differences were significantly amplified in hypertensive SHR rats. This highlights that disease states can unmask or create distinct arterial and venous miRNA signatures.
- Arterial miRNAs as Key Players in Hypertension: The study strongly suggests that arterial circulating miRNAs are more prominently associated with hypertension than venous miRNAs. This is supported by the higher number of deregulated arterial miRNAs and their stronger disease associations, particularly with cardiovascular conditions.
- Novel Arterial Biomarkers Identified: The research identified two specific arterial miRNAs, miR-455-3p and miR-140-3p, that showed consistent deregulation in hypertensive rats and were validated by ddPCR. These are proposed as novel potential prognostic biomarkers for hypertension.
- Re-evaluation of Venous Biomarkers: The findings challenge the sole reliance on venous miRNAs for hypertension biomarker discovery, suggesting that some previously identified venous biomarkers might not fully represent the disease's arterial impact.
Key Results
- In WKY rats, only 1 deregulated miRNA (rno-miR-483-3p) was found between arterial and venous blood.
- In 16-week-old SHR rats, 16 deregulated miRNAs were observed between arterial and venous blood.
- Bioinformatic analysis linked these deregulated miRNAs to cardiovascular disease-related functions, including hypoxia response, angiogenesis, and inflammation.
- Comparisons between SHR and WKY rats revealed more prominent disease associations for arterial miRNAs than venous miRNAs.
- Validation using ddPCR confirmed the differential expression of key arterial miRNAs (rno-miR-455-3p, rno-miR-181b-5p, rno-miR-140-3p, and rno-miR-493-5p) in arterial plasma of hypertensive rats.
- Specifically, rno-miR-455-3p and rno-miR-140-3p showed significantly reduced levels in young non-hypertensive JSHR rats compared to SHRs, supporting their potential as prognostic markers.
Limitations and Future Work
- Animal Model: The study was conducted in rat models. While valuable, further validation in human cohorts is essential to confirm the findings and the clinical utility of the identified biomarkers.
- MiRNA Carriers: The study focused on circulating miRNAs in plasma. Future work could explore miRNAs carried within extracellular vesicles or bound to proteins, as these might have different dynamics and implications.
- Mechanism Elucidation: While target genes and pathways were identified, a deeper understanding of the precise molecular mechanisms by which these arterial miRNAs contribute to or reflect hypertension pathogenesis is needed.
- Broader Disease Spectrum: The authors suggest that the phenomenon of arterial-venous miRNA differences might extend beyond hypertension to other diseases, warranting further investigation.
- Clinical Validation: The identified arterial miRNAs (miR-455-3p and miR-140-3p) require extensive clinical validation in human patients to establish their diagnostic and prognostic value.
Summary updated